Aflibercept/rinucumab - Regeneron Pharmaceuticals

Drug Profile

Aflibercept/rinucumab - Regeneron Pharmaceuticals

Alternative Names: Aflibercept/REGN 2176; Eylea/REGN-2176; Eylea/rinucumab; PDGFR-beta-Eylea combination therapy - Bayer/Regeneron; REGN-2176-3; REGN-2176/aflibercept; REGN-2176/Eylea; Rinucumab/aflibercept; Rinucumab/Eylea

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Wet age-related macular degeneration

Most Recent Events

  • 16 Feb 2017 Regeneron Pharmaceuticals terminates a phase II trial in Wet age related macular degeneration (In Adults, In the elderly) in USA and Japan (NCT02418754)
  • 01 Dec 2016 Discontinued - Phase-II for Wet age-related macular degeneration (In the elderly, In adults) in USA, Japan (Intravitreous)
  • 30 Sep 2016 Top-line efficacy and safety data from a phase II trial in Wet age-related macular degeneration released by Regeneron Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top